INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number Filing Date First Named Inventor Danie Art Unit		10712888			
		2003-11-12			
		d G. Dadourian			
		3734			
Examiner Name	Linds	ey M. Bachman			
Attorney Docket Number		NCPT-001			

U.S.PATENTS Remove								
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1	4606336		1986-08-19	Zeluff			
	2	4950227		1990-08-21	Savin, et al.			
	3	5540712		1996-07-30	Kleshinski, et al.			
	4	5667486		1997-09-16	Mikulich, et al.			
	5	5669932		1997-09-23	Fischell, et al.			
	6	5676670		1997-10-14	Km			
	7	5716393		1998-02-10	Lindenberg, et al.			
	8	5741333		1998-04-21	Frid			

9	5749825	1998-05-12	Fischell, et al.	
10	5749890	1998-05-12	Shaknovich	
11	5755769	1998-05-26	Richard, et al.	
12	5860999	1999-01-19	Schnepp-Pesch, et al.	
13	5976178	1999-11-02	Goldsteen, et al.	
14	6017324	2000-01-25	Tu	
15	6096071	2000-08-01	Yaday	
16	6099497	2000-08-08	Adams, et al.	
17	6136011	2000-10-24	Stambaugh	
18	6152944	2000-11-28	Holman, et al.	
19	6210380	2001-04-03	Mauch	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10712888		
Filing Date		2003-11-12		
First Named Inventor Danie		G. Dadourian		
Art Unit		3734		
Examiner Name Linds		ey M. Bachman		
Attorney Docket Number		NCPT-001		

	20	6334864		2002-01-01	Amplatz, et al.				
	21	6361544		2002-03-26	Wilson, et al.				
	22	6544219		2003-04-08	Happ, et al.				
	23	6558368		2003-05-06	Voda				
	24	6572612		2003-06-03	Stewart, et al.				
	25	6599316		2003-07-29	Vardi, et al.				
	26	6682556		2004-01-27	Ischinger				
	27	6719720		2004-04-13	Voelker, et al.				
	28	6821295		2004-11-23	Fапаг				
	29	7105015		2006-09-12	Goshgarian				
If you wis	sh to a	dd additional U.S. Paten	t citatio	n information pl	ease click the Add button.		Add		
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number Filing Date		10712888
			2003-11-12
	First Named Inventor	Danie	G. Dadourian
	Art Unit		3734
Examiner Name Linds		Linds	ey M. Bachman
	Attorney Docket Number		NCPT-001

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ition	Name of Patentee of Applicant		Rele	s,Columns, vant Passag es Appear		
	1	20030083734		2003-05	i-01	Holger, et al.					
	2	20040102838		2004-05	i-25	Killion, et al.					
	3	20040215186		2004-10	1-28	Comelius, et a	ı				
	4	20050049678		2005-03-03		Cooks, et al.					
	5	20050177221		2005-06	i-11	Mustapha					
If you wis	h to a	dd additional U.S. Publi						d butto			
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	i	Kind Code4	Publication Date	Name of Patente Applicant of cited Document		where Rele	or Relevant	74
	1	0876805	EΡ			1998-11-11	Turnland, et al.				
	2	990036015	wo			1999-07-22	Scott, et al.				
	3	0974314	EP			2000-01-26	Advanced Cardiova Systems, Inc.	ascular			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

1364676

EP

Application Number		10712888		
Filing Date		2003-11-12		
First Named Inventor	Danie	Daniel G. Dadourian		
Art Unit		3734		
Examiner Name	Lindsey M. Bachman			
Attorney Docket Number		NCPT-001		

Date Considered

2003-11-26 Kanegafuchi Chemical

	5	1512381	EP		2005-02-03	Cordis		_	
	6	2005009295	wo		2005-02-03	Advanced Stent Technologies			
	7	2005041810	wo		2005-05-12	Ben-Muvhar, et al.			
	8	2006085304	wo		2006-08-17	Ben-Muvhar			
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add button	n Add		
			NON-PATER	NT LITE	ERATURE DO	CUMENTS	Remove		
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the lem (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where publisher.								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a 1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO

If you wish to add additional non-patent literature document citation information please click the Add button Add EXAMINER SIGNATURE

citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Standard ST.3) 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10712888		
Filing Date		2003-11-12		
First Named Inventor	Danie	Daniel G. Dadourian		
Art Unit		3734		
Examiner Name	Lindsey M. Bachman			
Attorney Docket Number		NCPT-001		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make the	he appropriate selection(s):
---------------	----------	----------------------	------------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/william a. english/	Date (YYYY-MM-DD)	2007-05-09
Name/Brint	William A English	Registration Number	42515

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) and application. Confidentiality is governed by \$5 U.S. C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Pleater and Trademark Office, U.S. operatment of Commence, P.O. 8bs 1449, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bs 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.